Valuation : Turn Therapeutics Inc.

Market Cap 378M 326M 308M 280M 524M 36.11B 527M 3.66B 1.41B 18.37B 1.42B 1.39B 58.06B P/E 2026 *
-31.7x
P/E 2027 * -32.5x
Enterprise Value 378M 326M 308M 280M 524M 36.11B 527M 3.66B 1.41B 18.37B 1.42B 1.39B 58.06B EV / Sales 2026 *
756x
EV / Sales 2027 * 75.6x
Free-Float
45.25%
Yield 2026 *
-
Yield 2027 * -
1 day-5.16%
1 week+29.49%
Current month+32.19%
1 month+28.70%
3 months+109.93%
6 months+251.52%
Current year+222.08%
1 week 9.82
Extreme 9.82
14.39
1 month 9
Extreme 9
14.39
Current year 3.01
Extreme 3.01
14.39
1 year 2.57
Extreme 2.5701
26.5
3 years 2.57
Extreme 2.5701
26.5
5 years 2.57
Extreme 2.5701
26.5
10 years 2.57
Extreme 2.5701
26.5
Manager TitleAgeSince
Chief Executive Officer 48 05/01/2015
Director of Finance/CFO 31 30/04/2025
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman 48 -
Director/Board Member 46 30/09/2018
Director/Board Member 61 31/12/2019
Date Insider Type Main position Quantity % Market Cap. Importance
28/05/26 Don

Chief Executive Officer

-1,200,000 4.0285%
02/04/26 Don

Chief Executive Officer

300,000 1.0188%
02/04/26 Don

Director

300,000 1.0188%
Change 5-day change 1-year change 3-year change Capi.($)
-5.16%+29.49% - - 378M
-2.11%-1.68%+43.40%+95.58% 66.93B
-0.23%-4.45%+32.50%+77.58% 61.97B
+1.67%+2.47%-11.32%+392.05% 28.26B
+3.70%+0.58%+25.54%+16.37% 24.59B
+0.34%-6.78%-0.01%-14.59% 24.3B
+0.43%-3.37%+16.22%-17.48% 19.41B
-3.03%-2.29%+181.72%+333.47% 16.77B
+2.28%-3.06%-6.60%+539.41% 14.18B
+3.24%-0.31%-7.34%+833.51% 14B
Average +0.11%+0.30%+30.46%+250.66% 27.08B
Weighted average by Cap. +0.09%-2.78%+31.04%+173.45%

Financials

2026 *2027 *
Net sales 500K 431K 408K 370K 694K 47.77M 697K 4.84M 1.86M 24.3M 1.88M 1.84M 76.79M 5M 4.31M 4.08M 3.7M 6.94M 478M 6.97M 48.45M 18.63M 243M 18.78M 18.37M 768M
Net income - -
Net Debt - -
Logo Turn Therapeutics Inc.
Turn Therapeutics Inc. is a pharmaceutical and medical device development company built around a proprietary platform of technology designed to enhance drug performance. Its patented mixing process-commercially referred to as PermaFusion-enables stable suspension of polar, water-soluble active pharmaceutical ingredients (APIs) in oil-based carriers without the use of emulsifiers. Its primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Its products and programs include GX-03/Hexagen for Wounds (Hexagen (K160872)), GX-03/Hexagen for Derm (AtopX (K171191)), Sterile Gauze Impregnated with GX-03/Hexagen (XEAL (K183681)), Sterile Collagen/Hexagen Powder (FleX Product), GX-03/Hexagen for Moderate-Severe Eczema, and GX-03/Hexagen for Onychomycosis. GX-03/Hexagen for Wounds (Hexagen (K160872)) is a medical device for treating wounds and burns. GX-03/Hexagen for Derm (AtopX (K171191)) is a medical device for managing dermatitis.
Employees
-
Date Price Change Volume
11/09/26 US$12.69 -5.16% 135,664
10/09/26 US$13.38 -2.69% 125,078
09/09/26 US$13.75 +8.61% 277,536
08/09/26 US$12.66 +29.18% 321,761
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
12.69USD
Average target price
26.00USD
Spread / Average Target
+104.89%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TTRX Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!